Cullinan Therapeutics, Inc.CGEMNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+26.8%
5Y CAGR+34.1%
Year-over-Year Change
Research and development spending
3Y CAGR
+26.8%/yr
vs +76.0%/yr prior
5Y CAGR
+34.1%/yr
Recent deceleration
Acceleration
-49.2pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
4.3x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $187.40M | +31.1% |
| 2024 | $142.90M | -3.5% |
| 2023 | $148.16M | +61.1% |
| 2022 | $91.95M | +59.2% |
| 2021 | $57.75M | +33.6% |
| 2020 | $43.21M | +157.4% |
| 2019 | $16.79M | +75.2% |
| 2018 | $9.58M | - |